RAPT Therapeutics's 15min chart triggers Bollinger Bands Narrowing, Bearish Marubozu pattern.

RAPT Therapeutics's 15-minute chart has exhibited Bollinger Bands Narrowing, accompanied by a Bearish Marubozu pattern on August 11, 2025 at 15:30. This indicates a reduction in stock price volatility, indicating sellers are in control and a continuation of bearish momentum is likely.

Investing.com - Clear Street has recently raised its price target on Rapt Therapeutics (NASDAQ:RAPT) to $24.00 from $3.00 while maintaining a Buy rating. This move is driven by the potential of the company’s RPT904 antibody [1].

The firm points to forthcoming second-half 2025 data that will directly compare RPT904 with XOLAIR as a major catalyst for Rapt’s valuation. RPT904 is advancing for food allergy treatment with Phase 2b trials starting in the second half of 2025, while data from Rapt’s Chinese partner Jemincare on chronic spontaneous urticaria (CSU) and asthma applications is imminent [1].

Clear Street notes that RPT904 targets the same epitope as XOLAIR but features YTE mutations that extend its half-life, potentially allowing for less frequent dosing (every 2-12 weeks compared to XOLAIR’s biweekly schedule). The firm cites surveys indicating willingness among payers and prescribers to pay a 15% premium over XOLAIR’s branded price despite expected biosimilar competition by year-end 2026 [1].

The research firm highlights that RPT904’s streamlined dosing could potentially reach 30% of food allergy patients with higher body weight or elevated serum IgE levels who cannot currently use XOLAIR. The food allergy market remains largely untapped, as demonstrated by XOLAIR exceeding 60,000 patients and generating over $1 billion in its first full year [1].

Rapt Therapeutics maintains a cash position of $179.3 million, which Clear Street believes adequately funds the company through Phase 2b food allergy data expected in the first half of 2027 and the launch of a Phase 2/3 CSU trial in the second half of 2026. The price target adjustment also reflects Rapt’s 1-for-8 reverse stock split effective June 16, 2025, and Clear Street’s switch to using diluted share count for valuation calculations [1].

In other recent news, RAPT Therapeutics has been in the spotlight with several noteworthy developments. JPMorgan upgraded the company’s stock rating to Neutral from Underweight, citing the de-risked mechanism of its lead drug candidate RPT904, which shows promise in the Food Allergy and Chronic Spontaneous Urticaria markets. Meanwhile, H.C. Wainwright raised its price target for RAPT Therapeutics to $27 from $6, maintaining a Buy rating after Merck (NSE:PROR)’s acquisition of Verona Pharma (NASDAQ:VRNA), a company with FDA-approved treatments for chronic lung diseases. RAPT Therapeutics also announced the expansion of its Board of Directors, appointing Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., as new members. Dr. Braunstein will join the Audit Committee, while Dr. Dombkowski will be part of the Nominating and Corporate Governance Committee. Additionally, RAPT Therapeutics will implement a 1-for-8 reverse stock split, effective June 16, 2025, with trading on a split-adjusted basis commencing the following day. These developments reflect the company’s strategic moves and ongoing adjustments in its corporate structure [1].

References:
[1] https://za.investing.com/news/analyst-ratings/clear-street-raises-rapt-therapeutics-stock-price-target-to-24-on-rpt904-potential-93CH-3825042